Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KGX101 |
Synonyms | |
Therapy Description |
KGX101 is a prodrug comprising IL12 linked to an IL12RB-derived masking domain via a protease-sensitive linker that is cleaved by proteases in the tumor microenvironment, activating IL12 signaling and potentially stimulating an immune response and inhibiting tumor growth (Cancer Res (2024) 84 (6_Supplement): 4068). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KGX101 | KGX-101|KGX 101 | KGX101 is a prodrug comprising IL12 linked to an IL12RB-derived masking domain via a protease-sensitive linker that is cleaved by proteases in the tumor microenvironment, activating IL12 signaling and potentially stimulating an immune response and inhibiting tumor growth (Cancer Res (2024) 84 (6_Supplement): 4068). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06074497 | Phase I | KGX101 | A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |